कृपया अन्य खोज का प्रयास करें
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company’s preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Jean-Charles Soria | 50 | 2020 | Director |
Jan G.J. van de Winkel | 60 | 2017 | Independent Chairman of the Board |
Reinhard Kandera | 52 | 2017 | CFO & Director |
Joern Aldag | 62 | 2016 | CEO & Director |
Sander van Deventer | 68 | 2011 | Scientific Advisory Member |
David Ross Kaufman | 49 | 2019 | Independent Director |
Julie O'Neill | 56 | 2018 | Independent Non-Executive Director |
Timothy Reilly | 49 | 2022 | Independent Non-Executive Director |
Mary Theresa Coelho | 61 | 2023 | Independent Director |
Malte Peters | 62 | 2023 | Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है